MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase

被引:41
|
作者
Xu, Weidong [1 ]
Jiang, Huayong [1 ]
Zhang, Fuli [1 ]
Gao, Junmao [1 ]
Hou, Jun [1 ]
机构
[1] Mil Gen Hosp Beijing PLA, Dept Radiat Oncol, 5 Nanmencang, Beijing 100700, Peoples R China
关键词
colorectal cancer; microRNA-330; proliferation; chemosensitivity; 5-fluorouracil; thymidylate synthase; COLON-CANCER; RNA; STATISTICS; EXPRESSION; PREVENTION; RESISTANCE; LINES;
D O I
10.3892/ol.2017.5895
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is the third most common cancer in males and the second most common in females, worldwide. Currently, 5-fluorouracil (5-FU)-mediated chemotherapy is the adjuvant treatment for patients with CRC following surgical resection. However, a number of patients with CRC develop 5-FU resistance, which is a major challenge for the effective treatment of cancer. Therefore, it is important to investigate the molecular mechanisms underlying chemoresistance and the therapeutic treatments that may improve the treatment of CRC. The present study demonstrated that microRNA (miR)-330 was significantly downregulated in CRC tissues and cell lines. Ectopic miR-330 expression decreased cell proliferation and enhanced cell chemosensitivity to 5-FU via the cell apoptosis pathway in CRC. In addition, thymidylate synthase (TYMS) was revealed to he a direct target gene of miR-330 in CRC. Knockdown of TYMS inhibited CRC cell proliferation, and enhanced cell chemosensitivity to 5-FU by promoting cell apoptosis. In conclusion, the results of the present study indicated that miR-330 targeted TYMS to inhibit the proliferation and enhance the chemosensitivity of CRC cells to 5-FU by promoting cell apoptosis. The present study provided important insight into the molecular mechanism underlying 5-FU-mediated chemoresistance and a novel therapeutic strategy for the enhancement of efficacy in CRC treatment.
引用
收藏
页码:3387 / 3394
页数:8
相关论文
共 50 条
  • [41] Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer
    Fakhrejahani, Elham
    Miyamoto, Akiko
    Tanigawa, Nobuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (03) : 437 - 446
  • [42] Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
    Aschele, C
    Debernardis, D
    Bandelloni, R
    Cascinu, S
    Catalano, V
    Giordani, P
    Barni, S
    Turci, D
    Drudi, G
    Lonardi, S
    Gallo, L
    Maley, F
    Monfardini, S
    ANNALS OF ONCOLOGY, 2002, 13 (12) : 1882 - 1892
  • [43] Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays
    Shimizu, D
    Ishikawa, T
    Ichikawa, Y
    Togo, S
    Hayasizaki, Y
    Okazaki, Y
    Danenberg, PV
    Shimada, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (02) : 371 - 376
  • [44] Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients
    Kristensen, M. H.
    Pedersen, P. L.
    Melsen, G. V.
    Ellehauge, J.
    Mejer, J.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (03) : 870 - 883
  • [45] Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy
    Haritha, Nair Hariprasad
    Nawab, Akbar
    Vijayakurup, Vinod
    Anto, Nikhil Ponnoor
    Liju, Vijayasteltar B.
    Alex, Vijai V.
    Amrutha, Areekkara Nisthul
    Aiswarya, Sreekumar U.
    Swetha, Mundanattu
    Vinod, Balachandran S.
    Sundaram, Sankar
    Guijarro, Maria, V
    Herlevich, Thomas
    Krishna, Archana
    Nestory, Nesteena K.
    Bava, Smitha, V
    Sadasivan, Chittalakkottu
    Zajac-Kaye, Maria
    Anto, Ruby John
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Thymidylate Synthase Gene Polymorphism and Survival of Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil
    Sulzyc-Bielicka, Violetta
    Bielicki, Dariusz
    Binczak-Kuleta, Agnieszka
    Kaczmarczyk, Mariusz
    Pioch, Wieslawa
    Machoy-Mokrzynska, Anna
    Ciechanowicz, Andrzej
    Golebiewska, Magdalena
    Drozdzik, Marek
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2013, 17 (11) : 799 - 806
  • [47] A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
    B Iacopetta
    F Grieu
    D Joseph
    H Elsaleh
    British Journal of Cancer, 2001, 85 : 827 - 830
  • [48] Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression
    Xiao, Yang
    Yurievich, Usenko Alexander
    Yosypovych, Smorzhevskyi Valentyn
    ONCOTARGET, 2017, 8 (47) : 83171 - 83182
  • [49] Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil
    Hosokawa A.
    Yamada Y.
    Shimada Y.
    Muro K.
    Hamaguchi T.
    Morita H.
    Araake M.
    Orita H.
    Shirao K.
    International Journal of Clinical Oncology, 2004, 9 (5) : 388 - 392
  • [50] Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
    Hitre, E
    Budai, B
    Adleff, V
    Czeglédi, F
    Horváth, Z
    Gyergyay, F
    Lövey, J
    Kovács, T
    Orosz, Z
    Láng, I
    Kásler, M
    Kralovánszky, J
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) : 723 - 730